Intuitive Surgical(ISRG) has been a key topic amid concerns and expectations from investors. The company recently received FDA clearance for its revised da Vinci Xi and X labeling on Radical Prostatectomy and launched a new robotic system, both events having heightened investors' interest. Wall Street has been largely optimistic about ISRG, despite some indications of overpriced stocks. The company has reported robust Q4 earnings and shown strong preliminary Q4 results. Its stock saw a 20% YTD increase and hit a 52-week high on procedure demand. ISRG's robust performance, alongside autonomous operations, may threaten its moat in robotic surgery. Meanwhile, there has been an insider sell-off, with EVP & Chief Medical Officer Myriam Curet and director Craig Barratt selling company shares. Despite market fluctuations, the stock has largely outperformed competitors on heavy trading days, asserting ISRG's attractiveness to investors. The FDA's backing has been a significant boost, yet a Wall Street Analyst's prediction of 20% upside projects even more bullish trends.
Intuitive Surgical ISRG News Analytics from Fri, 01 Dec 2023 08:00:00 GMT to Fri, 07 Jun 2024 16:28:00 GMT -
Rating 8
- Innovation 5
- Information 6
- Rumor -2
